nach oben

Journal of Neural Transmission

Erschienen in:

25.02.2019 | Neurology and Preclinical Neurological Studies - Review Article

Classical dopamine agonists

verfasst von: R. Horowski, P.-A. Löschmann

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson’s disease (PD) with l-DOPA and subsequently dopaminergic drugs. Parenteral apomorphine has a short lasting effect in PD, bromocriptine can be administered orally and has a long-lasting effects but is poorly tolerated. Lisuride on the other hand has a high affinity to DA receptors and can be administered orally, parenterally or via the transdermal route of administration. Last but not least Carlsson developed the concepts of presynaptic effects of DA agonists as well as DA partial agonism potentially innovative mechanisms for treatment of PD and schizophrenia.

Andén NE, Rubenson A, Fuxe K, Hökfelt T (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol 19:627–629CrossRefPubMed

Birkmayer W, Riederer P (1983) Effects of lisuride on motor function and psychic behaviour. In: Calne DB, Horowski R, McDonald RM, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 453–461

Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A, Hacksell U (2011) In vitro evidence that (−)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm 118:1523–1533CrossRefPubMed

Calne DB, Teychenne PF, Claveria LF, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in Parkinson’s disease. Br Med J 5942:442–444CrossRef

Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11:490–493PubMed

Carlsson A, Lindquist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200CrossRefPubMed

Carlsson A, Dahlstroem A, Fuxe K, Lindquist M (1962) Histochemical and biochemical detection of monoamine release from brain neurons. Life Sci 4:809–8016CrossRef

Chiodini PG, Liuzzi A, Verde G, Cozzi R, Silvestrini F, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1980) Size reduction of a prolactin-secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin Endocrinol (Oxf) 12:47–51CrossRef

Elenkova A, Shabani R, Kalinov K, Zacharieva (2012) Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 167:17–25CrossRefPubMed

Ernst AM (1965) Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia 21:391–399CrossRef

Feser J (1873) Die in neuester Zeit in Anwendung gekommen Arzneimittel; Z Prakt. Veterinärwissenschaft 273, 306, quoted from R. Magnus, 1920

Flückiger E, Wagner HR (1968) 2-Br-alpha-Ergocryptin: Einfluss auf Fertilität und Laktation der Ratte. Experientia 24:1130–1131CrossRefPubMed

Fuxe K, Corrodi H, Hökfelt T, Lidbrink P, Ungerstedt U (1974) Ergocornine und 2-Br-alpha-ergocryptine: evidence for prolonged dopamine receptor stimulation. Med Biol 52:121–132PubMed

Gessa GL (1988) Agonist and antagonist effects of lisuride: electrophysiological evidence. J Neural Transm Suppl 27 201–210. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease, Springer Wien, New York

González-Maeso J, Weisstaub NY, Zhou M, Chan P, Iric L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogen signalling in cortical neurons. Neuron 53:439–452CrossRefPubMed

Gräf KJ, Neumann F, Horowski R (1976) Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98:598–605CrossRefPubMed

Herzog A, Minne H, Ziegler R (1989) Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine. BMJ 298:1315CrossRefPubMedPubMedCentral

Hofmann CH, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29:80–86CrossRefPubMed

Horowski R (1983) Pharmacological effects of lisuride. In: Calne DB, Horowski R, McDonald RM, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 127–139

Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 36:373–383CrossRefPubMed

Horowski R, Marsden CD, Obeso JA (1988) Continuous dopaminergic stimulation: state of the art and outlook. J Neural Transm Suppl 27:249–252. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. Springer Wien, New York

Horowski R, Dorow R, Löschmann P-A, Runge I, Wachtel H, Obeso JA (1989) Oral and parenteral use of lisuride in Parkinson’s disease. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy of Parkinson’s disease. Springer Wien, New York, pp 269–276CrossRef

Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptine—a review. Psychopharmacology 95:433–446CrossRefPubMed

Jähnichen S, Horowski R, Pertz HH (2006) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Clin Neuropharmacol 29:80–86CrossRefPubMed

Jurasz A (1875) Über die Wirkungen des salzsauren Apomorphins Dt. Arch Klin Med 16:41 (quoted from R. Magnus 1920)

Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43:2–11CrossRefPubMed

Lange KW, Löschmann PA, Wachtel H, Horowski R, Jähnig P, Jenner P, Marsden CD (1992) Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 212:247–252CrossRefPubMed

Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gräf KJ, Horowski R (1978) Lisuride hydrogen maleate: evidence for a long-lasting dopaminergic activity in humans. J Clin Endocrinol Metab 46:196–202CrossRefPubMed

Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659CrossRefPubMed

Löschmann PA, Horowski R, Wachtel H. Bromerguride - an ergoline derivative with atypical neuroleptic properties. Clin Neuropharmacol (1992)15(Suppl 1 Pt A):263A–264ACrossRefPubMed

Luquin MR, Obeso JA, Martínez-Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1987) Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 45:561–568PubMed

MacLeod RM, Lehmeyer JE (1974) Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94:1077–1085

Matthiesen A, Wright CRA (1869) Proc R Soc 17:455–460 (quoted from R. Magnus 1920) CrossRef

McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Parenteral administration of lisuride in Parkinson’s disease. Eur Neurol 22:240–255CrossRefPubMed

Pieri L, Keller HH, Burkard W, da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278–279CrossRefPubMed

Rehse K (1978) Neuropsychotrope Aktivität und Toxizität von Oxidationsprodukten des Apomorphin. Arch Pharm 311:360–363CrossRef

Seemann D, Danielczyk W, Ogris E, Jellinger K, Riederer P (1984) Dopaminergic agonists—effects on multiple receptor sites in Parkinson’s disease. In: Callaghan N, Galvin R (eds) Recent research in neurology. Pitman, Chichester, pp 49–60

Stocchi F (2008) Use of apomorphine in Parkinson’s disease. J Neurol Sci 29(Suppl 5):383–386. https://doi.org/10.1007/s10072-008-1053-8 CrossRef

Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Subcutaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm Suppl 27:27–33

Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 125:2058–2066CrossRefPubMed

Struppler A, Von Uexkull T (1953) Untersuchungen zum Wirkungsmechanismus von Apomorphin auf den Parkinson-Tremor. Z Klin Med 152:46–57PubMed

Svensson K, Eriksson E, Carlsson A (1993) Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 32:1037–1045CrossRefPubMed

Weil C (1986) The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 10:172–195CrossRefPubMed

Woitalla D, Müller T, Benz S, Horowski R, Przuntek H (2004) Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl 68:89–95

Wuttke W, Cassell E, Meites J (1971) Effects of ergocornine on serum prolactin and LH, and on hypothalamic content of PIF and LRF. Endocrinology 88:737–741CrossRefPubMed

Zikán V, Semonský M (1960) Mutterkornalkaloide XVI. Einige N-(d-6-methylisoergolenyl-8)-, N-(d-6-methylergolenyl-8)- und N-(d-6-methylergolin(I)-yl-8)-N′-substituierte Harnstoffe. Collect Czech Chem Commun 25:1922–1928CrossRef

Titel: Classical dopamine agonists
verfasst von: R. Horowski
P.-A. Löschmann
Publikationsdatum: 25.02.2019
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 4/2019
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-01989-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Classical dopamine agonists

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Dopamine in psychiatry: a historical perspective

On Nobel Laureate Arvid Carlsson

Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment

Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

Dopamine and addiction: what have we learned from 40 years of research

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie